Table 1.

Clinical trials of neoantigen vaccines.

ClinicalTrial.gov identifier	Phases	Enrollment status	Cancer type	Vaccine format	Additional intervention	Patient accrual target
NCT03558945	Phase 1	Recruiting	Pancreatic tumor	peptide	None	60
NCT04487093	Phase 1	Recruiting	Non small cell lung cancer	peptide	EGFR-TKI/anti-angioge	20
NCT04397926	Phase 1	Recruiting	Non small cell lung cancer	peptide	None	20
NCT02950766	Phase 1	Recruiting	Renal cell carcinoma	peptide	Ipilimumab	19
NCT03359239	Phase 1	Recruiting	Urothelial cancer	peptide	Atezolizumab	15
NCT02287428	Phase 1	Recruiting	Glioblastoma	peptide	Pembrolizumab	56
NCT03956056	Phase 1	Recruiting	Pancreatic cancer	peptide	None	15
NCT04117087	Phase 1	Recruiting	Colorectal cancer, pancreatic cancer	peptide	Nivolumab, ipilimumab	30
NCT04248569	Phase 1	Recruiting	Hepatocellular carcinoma	peptide	Nivolumab, ipilimumab	12
NCT04072900	Phase 1	Recruiting	Melanoma	peptide	Toripalimab	30
NCT03953235	Phase 1/2	Recruiting	Solid tumors	peptide	Nivolumab, ipilimumab	144
NCT03639714	Phase 1/2	Recruiting	Solid tumors	peptide	Nivolumab, ipilimumab	214
NCT04161755	Phase 1	Recruiting	Pancreatic cancer	peptide	Atezolizumab, mFOLFIRINOX	20
NCT04024878	Phase 1	Recruiting	Ovarian cancer	peptide	Nivolumab	30
NCT03552718	Phase 1	Recruiting	Solid tumors	peptide	None	16
NCT04251117	Phase 1/2	Recruiting	Hepatocellular carcinoma	DNA	Pembrolizumab	24
NCT03199040	Phase 1	Recruiting	Triple negative breast cancer	DNA	Durvalumab	24
NCT04015700	Phase 1	Recruiting	Glioblastoma	DNA	None	6
NCT03674073	Phase 1	Recruiting	Hepatocellular carcinoma	DC	None	24
NCT04105582	Phase 1	Recruiting	Triple negative breast cancer	DC	None	5
NCT04078269	Phase 1	Recruiting	Non small cell lung cancer	DC	None	6
NCT04147078	Phase 1	Recruiting	Solid tumors	DC	None	80

EGFR, Epidermal growth factor receptor; TKI, Tyrosine-kinase inhibitor; DC, Dendritic Cell.